Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE

Authors :: Lars H. Lindner
Alan Anthoney
Agnieszka Wozniak
Piotr Rutkowski
I. Hennig
Antoine Italiano
Bernd Kasper
Steinar Aamdal
Michael G Leahy
Sandrine Marreaud
Sebastian Bauer
Hans Gelderblom
Winette T. A. van der Graaf
Branko Zakotnik
Patrick Schöffski
Jean-Yves Blay
Sandra J. Strauss
Peter Reichardt
Birgit Geoerger
Silvia Stacchiotti
Source :: Journal of Clinical Oncology. 36:11540-11540
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 11540Background: ASPS is an orphan disease associated with rearrangement of transcription factor E3 (TFE3), leading to abnormal MET expression. We assessed crizotinib in pts with ASPS (NCT01524926)...

Subjects :: Cancer Research
Crizotinib
business.industry
Medizin
Cancer
TFE3
Disease
medicine.disease
Oncology
Metastatic Alveolar Soft Part Sarcoma
Cancer research
Medicine
In patient
business
medicine.drug

Tools